Interestingly, a meta-analysis involving seven studies with 2297 participants indicated that SGLT-2 inhibitor plus MET was superior to MET for weight control in people with type 2 diabetes for no more than 52 weeks (43). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.